Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

ry promising results, as standard platinum, 5-FU, and radiation-based regimens for this disease are accompanied by a high incidence of severe radiation esophagitis, requiring patients to receive nutrition through feeding tubes," said Dr. Safran. "Paclitaxel poliglumex's selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects we have observed in this phase 2 study. Our results justify proceeding to a randomized, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Dr. Safran added.

"We look forward to discussing with the Food and Drug Administration a potential phase III registration strategy for this indication," said Jack Singer, M.D., Chief Medical Officer at CTI. "This would be the first registration study for a radiation sensitizing agent in this indication."

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Ph
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 Dynatronics Corporation (the "Company") ... of rehabilitation and physical therapy products, announced today ... raise approximately $4,000,000 in a private placement financing ... its affiliates (together with its affiliates, "Prettybrook"), a ... industry. The financing will provide Dynatronics with additional ...
(Date:5/4/2015)... 4, 2015   Mallinckrodt plc (NYSE: MNK ... May 13, 2015, at the Bank of America Merrill Lynch ... in Las Vegas, Nev. ... Financial Officer, and Cole Lannum , Senior Vice President ... company in a session scheduled to begin at 3 p.m. ...
(Date:5/4/2015)... Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... of proprietary compounded drug therapies, today reported that it ... Wednesday, May 13, 2015.  The company will host a ... on the same day to discuss its financial results ... and webcast will be open to all listeners and ...
Breaking Medicine Technology:Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 3
... Scientific Corporation (NYSE: BSX ) today announced ... 60th Annual Scientific Session of the American College of ... "Twelve-month results from the PLATINUM Workhorse clinical trial ... Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our ...
... DIEGO, March 29, 2011 Awarepoint Corporation announced ... at the First Annual Digital Healthcare Innovation Summit ... Intercontinental New York Barclay in New York. Joining Deady on ... of Dell Healthcare Services and Kaveh Safavi, M.D., vice president ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:5/4/2015)... For partners who’d like to become ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional ... levels, Astroglide TTC™ is specially formulated to provide a ... Centers for Disease Control, an average of one ... sustaining a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
Breaking Medicine News(10 mins):Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2
... germ that caused the plague epidemic that ravaged medieval Europe ... form easier to treat//, according to a study published on ... both bubonic plague, the dreaded Black Death spread when people ... from one person to another through coughing or sneezing. ...
... has received a $3.5 million National Institute of Child ... research program// on autism and related developmental disorders. ... aspects and outcomes for affected patients. The project includes ... in infants at risk for the condition, and funds ...
... have found a new technique that employs RNA, a tiny ... to therapeutics// for conditions in which nudging a gene awake ... a novel research tool to investigate the role that genes ... appearing online at Nature Chemical Biology and in an upcoming ...
... by HealthGrades, a leading independent healthcare ratings company, patients ... better chance of surviving, on average, than those admitted ... have also found that the patients who undergo surgery ... lower risk of complications during their stay. ...
... Swedish researchers have found out that consuming the right type ... children are habituated to consume lesser quantities// of unsaturated fat ... healthy children in the age group of four was undertaken ... with good socio-economic background. ,This study revealed that ...
... Government has come down heavily on alternative therapists who ... are about one lakh therapists said to exist in ... tab on these professionals. On the other hand, completely ... Medical Council have strict rules and guidelines regarding their ...
Cached Medicine News:Health News:Scientists Find Potential Weakness In Plague Germ 2Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:28% Lower Mortality Rate In Top U.S. Hospitals 2
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
Inquire...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
Medicine Products: